Neuralink has responded to claims of inhumane treatment during the animal testing phases of various company products, stating that animal welfare is a priority. “At Neuralink, we are absolutely committed to working with animals in the most humane and ethical way possible.”
Last week, reports surfaced of a lawsuit against the University of California at Davis from the Physicians Committee of Responsible Medicine (PCRM). The suit claims that the facility “failed to provide dying monkeys with adequate veterinary care, used an unapproved substance known as “Bioglue” that killed monkeys by destroying portions of their brains, and failed to provide for the psychological well-being of monkeys assigned to the experiment.” Earlier today, Teslarati reported an extensive timeline of events from the beginning of the partnership between UC Davis and Neuralink to the most recent developments, which include the potential of videos and photographs of the animals involved in the testing. Teslarati obtained several copies of veterinarian records from autopsies of some monkeys used in the experiments.
Neuralink is now responding to the various claims of animal abuse in a lengthy statement that outlines the past, present, and future developments of Neuralink trials. The company maintains that all animals are treated respectfully and ethically.
EXCLUSIVE: Neuralink dragged into humane testing lawsuit – Timeline of Events
Neuralink ended its partnership with UC Davis in November 2020, just two months after PCRM sent a California Public Records request for information regarding the Neuralink trials. The request is eventually denied in accordance with California State Code 6255(a), which says that the Agency “shall justify withholding any record by demonstrating that the record in question is exempt under express provisions of this chapter or that on the facts of the particular case the public interest served by not disclosing the record clearly outweighs the public interest served by disclosure of the record.”
Neuralink took several of the monkeys back to its testing facilities in Northern California for in-house experiments. “Once construction of our in-house facility was completed, we were able to bring some unimplanted macaques from UC Davis with us to Neuralink. This included Pager, who would later be implanted with our Neuralink device and go on to achieve outstanding brain-computer interface performance, while freely behaving and unrestrained, as demonstrated in the Monkey MindPong video,” the company’s official response said. “While the facilities and care at UC Davis did and continue to meet federally mandated standards, we absolutely wanted to improve upon these standards as we transitioned animals to our in-house facilities.”
Neuralink says that “no injuries occurred at any time to animals housed at UC Davis” while the tests were ongoing. The company admits several animals were euthanized for research purposes, but they were done under controlled circumstances:
“The initial work from these procedures allowed us to develop our novel surgical and robot procedures, establishing safer protocols for subsequent survival surgeries. Survival studies then allowed us to test the function of different generations of implanted devices as we refined them towards human use. The use of every animal was extensively planned and considered to balance scientific discovery with the ethical use of animals. As part of this work, two animals were euthanized at planned end dates to gather important histological data, and six animals were euthanized at the medical advice of the veterinary staff at UC Davis. These reasons included one surgical complication involving the use of the FDA-approved product (BioGlue), one device failure, and four suspected device-associated infections, a risk inherent with any percutaneous medical device. In response we developed new surgical protocols and a fully implanted device design for future surgeries.”
Interestingly, PCRM said in a press release that “BioGlue” is an unapproved substance. FDA documents obtained by Teslarati show that BioGlue was approved for use in 2001, but the agency also included a warning of potential side effects when BioGlue is applied to the phrenic nerve. Application of BioGlue to this area in animals can cause acute nerve injury. Additionally, “BioGlue application to the surface of the heart can cause coagulation necrosis that extends into the myocardium, which could reach underlying conduction tissue and may cause acute, focal sinoatrial node degeneration,” the documents said. Five pigs were tested during initial animal experimentation while the FDA was determining BioGlue’s safety. All five pigs survived to the designated observation time.
Neuralink details humane animal treatment during Link v0.9 testing
Presently, the animals involved in Neuralink testing are housed at the company’s 6,000-square-foot facility that houses farm animals and rhesus macaques. The company takes care of the animals from the time they enter the facility to the time they leave, even detailing an animal’s process for “retirement:”
“Can we release the animals that regularly choose not to participate or who have completed their contribution to the study? Yes! We opted to retire animals at the conclusion of their projects. We retired several macaques to a sanctuary last March because they consistently chose to spend their day swimming in their pools, foraging, and relaxing in their hammocks rather than attending the game we presented to them. Their brand new enclosures and sanctuary costs were fully funded by Neuralink.”
Moving forward, Neuralink says it is always working to improve the current standards for animal well-being. “We also look forward to a day where animals are no longer necessary for medical research. Yet our society currently relies on medical breakthroughs to cure diseases, prevent the spread of viruses, and create technology that can change how people are able to interact with the world. However, if animals must be used in research in the meantime, their lives and experiences should be as vital and naturalistic as possible. We will always strive to surpass the industry standard and never stop asking ourselves: “Can we do better for the animals?”, and never forget it is a privilege to work with animals in research. It is our responsibility as caretakers to ensure that their experience is as peaceful and frankly, as joyful as possible.”
Neuralink’s complete statement is available here.
I’d love to hear from you! If you have any comments, concerns, or questions, please email me at joey@teslarati.com. You can also reach me on Twitter @KlenderJoey, or if you have news tips, you can email us at tips@teslarati.com.
Ferrari’s first electric vehicle, the Luce, is fully sold out for 2027, according to CEO Benedetto Vigna.
Presenting third-quarter results, he stated: “Everything we plan to sell next year is already fully allocated. Client test drives, scheduled for next year, will help further boost demand. We have no critical issues, neither on manufacturing nor on the demand side. Obviously, the car is more complex because it has many new parts and many new technologies.”
First customer deliveries are expected before the end of 2026, with the model already commanding waitlists despite a turbulent debut.
The Luce is a five-seat, four-door liftback saloon—the longest Ferrari ever produced—powered by four electric motors producing approximately 1,035 horsepower.
It features an 800-volt architecture, a 122-kWh battery, a claimed WLTP range of around 329 miles, 0-62 mph acceleration in 2.5 seconds, and a starting price near €550,000 in Europe (roughly $560,800–$615,000 in the U.S. depending on configuration).
Developed in collaboration with Jony Ive and Marc Newson’s LoveFrom studio alongside Ferrari’s own Centro Stile, it represents a deliberate departure from the brand’s traditional mid-engine sports cars toward a more spacious, grand-touring format.
Its exterior has proven deeply polarizing. Unveiled in Rome in May 2026, the design features smooth, sweeping surfaces, a large glass roof, and restrained detailing that critics described as bland, generic, or more reminiscent of an Apple product or mass-market EV than a Ferrari.
Ferrari unveils its Luce EV, and its reception has been a disaster
Online reactions included memes comparing it to a Nissan Leaf or Polestar, while former Ferrari chairman Luca di Montezemolo publicly warned of “the destruction of a myth” and suggested the prancing horse logo be removed. Italian politicians and longtime owners joined the chorus of disappointment, and Ferrari’s shares dropped roughly 8% in a single day, erasing billions in market value.
Design experts noted the absence of the brand’s signature tension, aggression, and emotional drama.
Yet the controversy has not translated into weak demand among the ultra-wealthy clientele who actually buy Ferraris. Production volumes remain tightly limited, as reports suggest fewer than 500 units in the current year and a longer-term pace of roughly 600 annually through 2030, preserving exclusivity.
One early chassis sold for $40 million at auction. Vigna has indicated that seeing the car in person, along with upcoming client test drives, is expected to strengthen rather than weaken interest. Ferrari aims for fully electric models to comprise 20 percent of its lineup by 2030, with a second EV now delayed to 2028.
For a brand defined by scarcity and desirability, the Luce’s sell-out status suggests that among those who can afford it, the polarizing design has not proven to be a commercial liability.
Tesla and SpaceX shares fell on Wednesday after Democrats swept both chambers of Congress. The decline stood out as broader market securities recovered and turned positive, while both of Musk’s publicly traded companies lagged.
CEO Elon Musk already joked about the unsuccessful campaigning for the Republicans, but now the new party will make pretty drastic changes to how it handles Tesla and SpaceX, and those companies will adjust their outlook.
Let’s take a deeper look.
Tesla ($TSLA)
Tesla shares traded lower during the regular session after Democrats secured both the House and Senate. The stock was down 2.32 percent at around 1:45 p.m. on the East Coast, trading at around $389.30.
The pressure is tied to more than the raw scale of Musk’s political spending, estimated at $450–474 million this cycle with roughly $224 million directed at Texas. In that state, Tesla now faces a Democratic governor and a Democratic senator after Gina Hinojosa unseated Greg Abbott and James Talarico defeated Ken Paxton.
The Austin Gigafactory, Robotaxi pilot programs in multiple Texas cities, and any related AI compute expansion sit under a new state executive who campaigned against certain corporate subsidies and floated a moratorium on new data-center construction.
Federally, Democratic control of key committees opens the door to deeper examination of Tesla’s autonomous-driving safety record, federal energy-storage and manufacturing incentives, and the national-security implications of any combination with SpaceX.
Investors are also weighing whether the company’s historically close alignment with the prior Republican leadership will invite slower permitting, additional hearings, or tighter rules on Full Self-Driving deployment.
For Tesla, the political shift adds near-term friction around state permitting and federal regulatory approvals for autonomy and energy storage. A potential merger with SpaceX may face slower review even if it proceeds.
Core growth drivers such as vehicle deliveries, energy deployments, and robotaxi rollout remain intact, yet the stock now carries a higher political-risk premium that could weigh on valuation until the company demonstrates workable relationships with the new Texas leadership and congressional majorities.
SpaceX ($SPCX)
SpaceX shares also declined in live trading on November 4 following the Democratic midterm sweep. The stock traded at $134.97, down 4.49 percent. The drop occurred even as broader indexes stabilized, highlighting a company-specific reaction to the election outcome.
Musk’s large contributions, concentrated in Texas races that both companies lost, place SpaceX’s Starbase launch facility and headquarters under a new Democratic governor.
At the federal level, Democratic control of Congress enables greater scrutiny of NASA, the Department of Defense, and other contracts that support a meaningful share of revenue, along with reviews of Starlink national-security uses and any Tesla merger. Analysts have noted that empowered committees can hold hearings and request documents on these relationships.
For SpaceX, the results raise the risk of delayed contract awards, higher compliance costs, and tighter constraints on AI and satellite infrastructure expansion, particularly in Texas where a data-center moratorium has been discussed.
A merger with Tesla could encounter political friction that slows integration of launch, connectivity, and autonomy capabilities.
While Starlink growth and launch cadence continue as primary drivers, the company faces a more contested path for federal funding and state-level operations, requiring management to rebuild ties with the new congressional majorities and Texas leadership to limit the overhang.
Tesla’s new vehicle registrations in Germany rose sharply in October, nearly quadrupling from the same month a year earlier. That’s according to data from the KBA, Germany’s federal motor transport authority.
The KBA reported 2,932 Tesla vehicles registered in October, a 290.9 percent year-over-year- increase. For the first ten months of the year, Tesla’s cumulative registrations reached 47,742 units. This number is up 206.1 percent compared with the January-October period of 2025. These gains occurred against a backdrop of strong overall growth in the BEV sector as a whole.
Germany registered 94,086 new BEVs in October, a 79.5 percent rise that brought the BEV share of the passenger car market to 37 percent of the 254,492 total cars registered that month.
🇩🇪 Tesla’s new registrations in Germany nearly quadrupled in October, according to KBA data.
October: 2,932 units, +290.9% YoY Jan–Oct: 47,742 units, +206.1%
Germany’s overall BEV market grew 79.5% to 94,086 units last month. https://t.co/GMwNqsFAOC
— TESLARATI (@Teslarati) November 4, 2026
Despite the percentage surge, Tesla’s absolute numbers left it with a 1.2 percent share of all new car registrations for October. Chinese competitors did record higher volumes, as BYD registered 5,173 vehicles, a 2 percent share, Leapmotor with 3,661 cars, which equates to 1.4 percent, and Xpeng had a 0.5 percent share.
Year-to-date through October, BYD edged ahead of Tesla with 47,961 registrations versus Tesla’s 47,742.
The October results follow a notably strong September for Tesla in Germany, when it registered 12,552 vehicles, an increase of roughly 269 percent year-over-year and one of its strongest monthly totals on record in the country. That month, the Model Y led all EVs and ranked among the top-selling vehicles of any powertrain.
The figures form part of a broader recovery in Tesla’s European registrations after an extended period of softer demand. While monthly volumes remain subject to typical quarter-end patterns and competitive pressure from both established European brands and rapidly expanding Chinese manufacturers, the year-to-date growth indicates improved traction in Europe’s largest car market.
Tesla’s Gigafactory Berlin-Brandenburg continues to supply the region, positioning the company to capture a share of the expanding German BEV market as overall EV adoptions looks to be accelerating.
Ferrari Luce sold out for 2027 after design controversy
Musk’s Tesla and SpaceX decline after Democratic Midterm sweep
